Recipharm Invests in BFS Technology

Article

Kaysersberg facility’s Lab+ deal expected to bolster CDMO’s filling services

Recipharm has boosted its sterile filling capabilities by investing in Lab+ technology for low volume blow-fill-seal (BFS) filling at its facility in Kaysersberg, France.

BFS is an automated manufacturing process where plastic ampoules are blow-formed, filled, and sealed in a continuous operation. The contract development and manufacturing organization (CDMO) provides sterile BFS contract manufacturing for a range of pharma products and applications including gels, solutions, suspensions, emulsions, and aseptically packed single-use vaccines.

With a throughput speed of 2,000 doses per hour and a flexible design, Lab+ is ideal for BFS projects that require smaller volumes. With a streamlined tooling changeover process, this tech is able to be adapted for a range of different product types and dosage designs. The system can also be charged with formulation using both conventional stainless-steel vessels or single-use charge bags.

“ … This new machinery means we can make small batches and removes the need to dedicate a whole filling line to one project. We can offer a system that is new, and rare on the market, allowing our customers to design and test their products, to see how they will look and react in a BFS system,” says Yves Buelens, site manager at Recipharm.

Read more about the investment here.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.